The immunosuppressive tumor environment limits this activation; however, this can be overcome by engineering a chimeric receptor that fuses this NKG2D activating receptor to CD3ζ in order to enable NKG2D.ζ CAR-NK cells to eliminate MDSC in vivo [158,160]. This evidence concerns the gene KLRK1 and neoplasm.